Which has better earnings and valuation, IMVT or SLS?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.78 N/A SELLAS Life Sciences Group N/A N/A -$26.86M -$0.23 N/A

Is IMVT or SLS more profitable?

SELLAS Life Sciences Group's return on equity of -47.12% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% SELLAS Life Sciences Group N/A -47.12% -42.63%

Does the media refer more to IMVT or SLS?

In the previous week, Immunovant had 2 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 8 mentions for Immunovant and 6 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.82 beat Immunovant's score of 0.42 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SELLAS Life Sciences Group 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KYMR or SLS?

In the previous week, Kymera Therapeutics had 2 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 8 mentions for Kymera Therapeutics and 6 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.82 beat Kymera Therapeutics' score of 0.48 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SELLAS Life Sciences Group 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LNTH or SLS?

In the previous week, Lantheus and Lantheus both had 6 articles in the media. SELLAS Life Sciences Group's average media sentiment score of 0.82 beat Lantheus' score of 0.46 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SELLAS Life Sciences Group 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SLS or PTGX?

In the previous week, Protagonist Therapeutics had 2 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 8 mentions for Protagonist Therapeutics and 6 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.82 beat Protagonist Therapeutics' score of 0.73 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SYRE or SLS more profitable?

Spyre Therapeutics' return on equity of -42.88% beat SELLAS Life Sciences Group's return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -42.88% -27.76% SELLAS Life Sciences Group N/A -47.12% -42.63%

Does the media refer more to SYRE or SLS?

In the previous week, SELLAS Life Sciences Group had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 6 mentions for SELLAS Life Sciences Group and 4 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 1.27 beat SELLAS Life Sciences Group's score of 0.82 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SELLAS Life Sciences Group 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SELLAS Life Sciences Group (SLS) Competitors

$8.18 -0.15 (-1.74%)

As of 02:27 PM Eastern

Compare

SLS vs. IMVT, KYMR, LNTH, PTGX, and SYRE

Should you buy SELLAS Life Sciences Group stock or one of its competitors? MarketBeat compares SELLAS Life Sciences Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SELLAS Life Sciences Group include Immunovant (IMVT), Kymera Therapeutics (KYMR), Lantheus (LNTH), Protagonist Therapeutics (PTGX), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does SELLAS Life Sciences Group compare to Immunovant?

Immunovant (NASDAQ:IMVT) and SELLAS Life Sciences Group (NASDAQ:SLS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Immunovant has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market.

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Immunovant had 2 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 8 mentions for Immunovant and 6 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.82 beat Immunovant's score of 0.42 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SELLAS Life Sciences Group	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant presently has a consensus price target of $37.33, indicating a potential upside of 21.39%. SELLAS Life Sciences Group has a consensus price target of $10.00, indicating a potential upside of 22.17%. Given SELLAS Life Sciences Group's higher possible upside, analysts plainly believe SELLAS Life Sciences Group is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

SELLAS Life Sciences Group's return on equity of -47.12% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

Summary

SELLAS Life Sciences Group beats Immunovant on 7 of the 13 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and SELLAS Life Sciences Group (NASDAQ:SLS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Kymera Therapeutics currently has a consensus price target of $118.10, suggesting a potential upside of 61.56%. SELLAS Life Sciences Group has a consensus price target of $10.00, suggesting a potential upside of 22.17%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

SELLAS Life Sciences Group has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Kymera Therapeutics had 2 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 8 mentions for Kymera Therapeutics and 6 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.82 beat Kymera Therapeutics' score of 0.48 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SELLAS Life Sciences Group	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kymera Therapeutics has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market.

SELLAS Life Sciences Group has lower revenue, but higher earnings than Kymera Therapeutics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	153.35	-$311.35M	-$3.57	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

Summary

Kymera Therapeutics beats SELLAS Life Sciences Group on 10 of the 16 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Lantheus?

Lantheus (NASDAQ:LNTH) and SELLAS Life Sciences Group (NASDAQ:SLS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

In the previous week, Lantheus and Lantheus both had 6 articles in the media. SELLAS Life Sciences Group's average media sentiment score of 0.82 beat Lantheus' score of 0.46 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SELLAS Life Sciences Group	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.25	$233.56M	$4.15	24.23
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

Lantheus presently has a consensus price target of $101.86, suggesting a potential upside of 1.29%. SELLAS Life Sciences Group has a consensus price target of $10.00, suggesting a potential upside of 22.17%. Given SELLAS Life Sciences Group's higher probable upside, analysts clearly believe SELLAS Life Sciences Group is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lantheus has a net margin of 18.05% compared to SELLAS Life Sciences Group's net margin of 0.00%. Lantheus' return on equity of 29.32% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

Lantheus has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.5, indicating that its stock price is 150% more volatile than the broader market.

Summary

Lantheus beats SELLAS Life Sciences Group on 11 of the 14 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Protagonist Therapeutics?

SELLAS Life Sciences Group (NASDAQ:SLS) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

SELLAS Life Sciences Group has higher earnings, but lower revenue than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A
Protagonist Therapeutics	$46.02M	131.12	-$130.15M	-$1.81	N/A

SELLAS Life Sciences Group has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

In the previous week, Protagonist Therapeutics had 2 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 8 mentions for Protagonist Therapeutics and 6 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.82 beat Protagonist Therapeutics' score of 0.73 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group has a beta of 2.5, indicating that its stock price is 150% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market.

SELLAS Life Sciences Group presently has a consensus price target of $10.00, indicating a potential upside of 22.17%. Protagonist Therapeutics has a consensus price target of $115.21, indicating a potential upside of 22.79%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protagonist Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Protagonist Therapeutics beats SELLAS Life Sciences Group on 10 of the 16 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and SELLAS Life Sciences Group (NASDAQ:SLS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Spyre Therapeutics has a beta of 3.05, suggesting that its stock price is 205% more volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market.

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

SELLAS Life Sciences Group has lower revenue, but higher earnings than Spyre Therapeutics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	7,079.90	-$155.20M	-$2.08	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

In the previous week, SELLAS Life Sciences Group had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 6 mentions for SELLAS Life Sciences Group and 4 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 1.27 beat SELLAS Life Sciences Group's score of 0.82 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SELLAS Life Sciences Group	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics' return on equity of -42.88% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

Spyre Therapeutics currently has a consensus price target of $90.25, suggesting a potential upside of 24.38%. SELLAS Life Sciences Group has a consensus price target of $10.00, suggesting a potential upside of 22.17%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Spyre Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Spyre Therapeutics beats SELLAS Life Sciences Group on 12 of the 15 factors compared between the two stocks.

Get SELLAS Life Sciences Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLS vs. The Competition

Export

Metric	SELLAS Life Sciences Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.52B	$3.27B	$6.26B	$12.43B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-35.59	17.91	22.42	24.23
Price / Sales	N/A	322.86	548.01	125.38
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	17.79	6.59	9.82	6.71
Net Income	-$26.86M	$24.20M	$3.56B	$337.09M
7 Day Performance	-4.60%	-3.13%	-1.17%	0.63%
1 Month Performance	66.02%	0.44%	3.71%	5.15%
1 Year Performance	399.09%	46.70%	27.28%	34.36%

SELLAS Life Sciences Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLS SELLAS Life Sciences Group	1.9039 of 5 stars	$8.21 -1.5%	$10.00 +21.8%	+427.2%	$1.53B	N/A	N/A	10	Gap Down
IMVT Immunovant	2.507 of 5 stars	$32.86 -1.3%	$37.33 +13.6%	+100.6%	$6.84B	N/A	N/A	120
KYMR Kymera Therapeutics	2.2548 of 5 stars	$78.47 -3.6%	$118.10 +50.5%	+65.3%	$6.70B	$39.21M	N/A	170
LNTH Lantheus	2.2554 of 5 stars	$97.13 -2.2%	$101.86 +4.9%	+24.9%	$6.47B	$1.55B	23.40	1,193	Gap Down
PTGX Protagonist Therapeutics	2.6064 of 5 stars	$94.92 -4.7%	$115.21 +21.4%	+85.8%	$6.40B	$74.06M	N/A	120	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLS) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SELLAS Life Sciences Group (SLS) Competitors

SLS vs. IMVT, KYMR, LNTH, PTGX, and SYRE

How does SELLAS Life Sciences Group compare to Immunovant?

Summary

How does SELLAS Life Sciences Group compare to Kymera Therapeutics?

Summary

How does SELLAS Life Sciences Group compare to Lantheus?

Summary

How does SELLAS Life Sciences Group compare to Protagonist Therapeutics?

Summary

How does SELLAS Life Sciences Group compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS vs. The Competition

SELLAS Life Sciences Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SELLAS Life Sciences Group (SLS) Competitors

SLS vs. IMVT, KYMR, LNTH, PTGX, and SYRE

How does SELLAS Life Sciences Group compare to Immunovant?

Which has more risk & volatility, IMVT or SLS?

Which has better earnings and valuation, IMVT or SLS?

Do insiders & institutionals believe in IMVT or SLS?

Does the media refer more to IMVT or SLS?

Do analysts recommend IMVT or SLS?

Is IMVT or SLS more profitable?

Summary

How does SELLAS Life Sciences Group compare to Kymera Therapeutics?

Do analysts recommend KYMR or SLS?

Is KYMR or SLS more profitable?

Do institutionals & insiders have more ownership in KYMR or SLS?

Does the media prefer KYMR or SLS?

Which has more volatility and risk, KYMR or SLS?

Which has stronger earnings & valuation, KYMR or SLS?

Summary

How does SELLAS Life Sciences Group compare to Lantheus?

Does the media refer more to LNTH or SLS?

Which has stronger valuation and earnings, LNTH or SLS?

Do analysts recommend LNTH or SLS?

Do institutionals and insiders have more ownership in LNTH or SLS?

Is LNTH or SLS more profitable?

Which has more risk and volatility, LNTH or SLS?

Summary

How does SELLAS Life Sciences Group compare to Protagonist Therapeutics?

Which has higher valuation and earnings, SLS or PTGX?

Is SLS or PTGX more profitable?

Does the media favor SLS or PTGX?

Which has more risk and volatility, SLS or PTGX?

Do analysts recommend SLS or PTGX?

Do institutionals and insiders hold more shares of SLS or PTGX?

Summary

How does SELLAS Life Sciences Group compare to Spyre Therapeutics?

Which has more volatility and risk, SYRE or SLS?

Do insiders & institutionals hold more shares of SYRE or SLS?

Which has higher valuation and earnings, SYRE or SLS?

Does the media refer more to SYRE or SLS?

Is SYRE or SLS more profitable?

Do analysts rate SYRE or SLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS vs. The Competition

SELLAS Life Sciences Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools